NCT04245722 - FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2020

Primary Completion Date

September 27, 2023

Study Completion Date

September 27, 2023

Conditions

Lymphoma, B-CellChronic Lymphocytic Leukemia

Interventions

DRUG

FT596

Experimental Interventional Therapy

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

DRUG

Rituximab

Monoclonal Antibody

DRUG

Obinutuzumab

Monoclonal Antibody

DRUG

Bendamustine

Conditioning agent

Trial Locations (9)

10016

NYU Langone Health, New York

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Sarah Cannon Research Institute (Tennessee Oncology), Nashville

55455

University of Minnesota Masonic Cancer Center, Minneapolis

60637

The University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

78229

SCRI-TTI, San Antonio

98104

Swedish Cancer Institute, Seattle